Inhibrx Biosciences Insider Bought Shares Worth $1,523,620, According to a Recent SEC Filing
JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
JMP Securities Sticks to Their Hold Rating for Inhibrx Biosciences Inc (INBX)
The Recent Drop in Prices Must Have Disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) Institutional Investors Who Own 43% of the Shares
Inhibrx Biosciences | 10-Q: Quarterly report
Inhibrx Biosciences | 8-K: Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Express News | Inhibrx Q3 Operating Income USD -46.797 Million
Inhibrx Biosciences 3Q Rev Negative $119,000 >INBX
Inhibrx Biosciences 3Q Loss $43.9M >INBX
Inhibrx Biosciences 3Q Loss/Shr $2.84 >INBX
Inhibrx: Jury Found in Favor of Inhibrx, Rejecting All Allegations of Misappropriation >INBX
Express News | Inhibrx Biosciences Inc: Legal Victory in a Trade Secrets Case Brought by I-Mab Biopharma
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
Inhibrx Biosciences Insider Bought Shares Worth $1,037,328, According to a Recent SEC Filing
Inhibrx Gains After Insider Purchases From CEO
Inhibrx Biosciences, Inc. GAAP EPS of $125.40, Revenue of $100M
Earnings Flash (INBX) INHIBRX BIOSCIENCES Posts Q2 Revenue $100,000
Inhibrx Biosciences Q2 EPS $125.48, Sales $100.00K Up From $30.00K YoY
JMP Securities Remains a Hold on Inhibrx Biosciences Inc (INBX)